NCI Alliance for Nanotechnology in Cancer – from academic research to clinical interventions

  • Piotr GrodzinskiEmail author
  • Christina H. Liu
  • Christopher M. Hartshorn
  • Stephanie A. Morris
  • Luisa M. Russell
Part of the following topical collections:
  1. Biomedical Micro-Nanotechnologies toward Translation


The National Cancer Institute (NCI) of National Institutes of Health has funded and operated the NCI Alliance for Nanotechnology in Cancer - a large multi-disciplinary program which leverages research at the intersection of molecular biology, oncology, physics, chemistry, and engineering to develop innovative cancer interventions. The program has demonstrated that convergence of several scientific disciplines catalyzes innovation and progress in cancer nanotechnology and advances its clinical translation. This paper takes a look at last thirteen years of the Alliance program operations and delineates its outcomes, successes, and outlook for the future.


Cancer nanotechnology Nanomedicine, multi-disciplinary research Federal funding 



  1. S. Chapman, N.J. Panaro, G.W. Hinkal, S.S. Hook, U. Prabhakar, K. Ptak, D. Farrell, P. Grodzinski, Kindling translational cancer nanotechnology research. Nanomedicine (London) 7, 321–325 (2012)CrossRefGoogle Scholar
  2. F. Currell, M. Bellringer, Cancer nanotechnology startup challenge: A new way to realize the fruits of innovation. Cancer Nanotechnology 7(2) (2016)Google Scholar
  3. A. Dickherber, S.A. Morris, P. Grodzinski, NCI investment in nanotechnology: Achievements and challenges for the future. Wiley Interdiscip Rev Nanomed Nanobiotechnol 7, 251 (2015)CrossRefGoogle Scholar
  4. D. Farrell, J. Alper, K. Ptak, N.J. Panaro, P. Grodzinski, A.D. Barker, Recent advances from the National Cancer Institute Alliance for nanotechnology in Cancer. ACS Nano 4, 589 (2010)CrossRefGoogle Scholar
  5. D. Farrell, K. Ptak, N.J. Panaro, P. Grodzinski, Nanotechnology-based cancer therapeutics-promise and challenge-lessons learned through the NCI Alliance for nanotechnology in Cancer. Pharm. Res. 28, 273–278 (2011)CrossRefGoogle Scholar
  6. M. Ferrari, Cancer nanotechnology: Opportunities and challenges. Nat. Rev. Cancer 5, 161 (2005)CrossRefGoogle Scholar
  7. P. Grodzinski, D. Farrell, Future opportunities in cancer nanotechnology--NCI strategic workshop report. Cancer Res. 74, 1307 (2014)CrossRefGoogle Scholar
  8. C.M. Hartshorn, M.S. Bradbury, G.M. Lanza, A.E. Nel, J. Rao, A.Z. Wang, U.B. Wiesner, L. Yang, P. Grodzinski, Nanotechnology strategies to advance outcomes in clinical Cancer care. ACS Nano 12, 24 (2018)CrossRefGoogle Scholar
  9. B.I. Hutchins, X. Yuan, J.M. Anderson, G.M. Santangelo, Relative citation ratio (RCR): A new metric that uses citation rates to measure influence at the article level. PLoS Biol. 14, e1002541 (2016)CrossRefGoogle Scholar
  10. T. Lenoir, P. Herron, The NCI and the takeoff of nanomedicine. J Nanomedine Biotherapeutic Discovery 5, 2 (2015)Google Scholar
  11. L.A. Nagahara, J.S. Lee, L.K. Molnar, N.J. Panaro, D. Farrell, K. Ptak, J. Alper, P. Grodzinski, Strategic workshops on cancer nanotechnology. Cancer Res. 70, 4265 (2010)CrossRefGoogle Scholar
  12. U. Prabhakar, D.C. Blakey, H. Maeda, R.K. Jain, E.M. Sevick-Muraca, W. Zamboni, O.C. Farokhzad, S.T. Barry, A. Gabizon, P. Grodzinski, Challenges and key considerations of the enhanced permeability and retention effect (EPR) for nanomedicine drug delivery in oncology. Cancer Res. 73, 2412 (2013)CrossRefGoogle Scholar
  13. R. Truman, C.J. Locke, Gazelles, unicorns, and dragons battle cancer through the nanotechnology startup challenge. Cancer Nanotechnol 7, 4 (2016)CrossRefGoogle Scholar
  14. W.C. Zamboni, V. Torchilin, A.K. Patri, J. Hrkach, S. Stern, R. Lee, A. Nel, N.J. Panaro, P. Grodzinski, Best practices in cancer nanotechnology: Perspective from NCI nanotechnology Alliance. Clin. Cancer Res. 18, 3229 (2012)CrossRefGoogle Scholar

Copyright information

© This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply 2019

Authors and Affiliations

  • Piotr Grodzinski
    • 1
    Email author
  • Christina H. Liu
    • 1
  • Christopher M. Hartshorn
    • 1
  • Stephanie A. Morris
    • 2
  • Luisa M. Russell
    • 1
  1. 1.Nanodelivery Systems and Devices Branch, Cancer Imaging Program, Division of Cancer Treatment and DiagnosisNational Cancer InstituteRockvilleUSA
  2. 2.NIH Office of Strategic CoordinationNational Institutes of HealthBethesdaUSA

Personalised recommendations